Answers are grounded in this paper and cite their sources.
Combination therapy shows synergistic effects on apoptosis in glioblastoma, indicating potential for further preclinical evaluation.
The combination of bevacizumab, carmustine, and metformin exerts a potent synergistic antitumor effect in U87MG glioblastoma cells through modulation of inflammation-associated genes, induction of apoptosis, and disruption of cell cycle progression. These findings provide a mechanistic rationale for multi-targeted combination therapy in glioblastoma and support further preclinical evaluation.
No takes yet. Share an insight, caveat, or question.
Norollahi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: